We offer three cardiovascular disease therapies including two oral treatments, based on a unique mechanism of action, approved in the U.S. and over 40 countries across the globe for cholesterol management and cardiovascular risk reduction, and the only FDA-approved nasal spray loop diuretic for short-term use in heart failure, renal disease, and hepatic disease. By partnering with commercial organizations, we’re working to enable broad access to our medicines globally.
Our scientific team is leading the investigation of ACLY biology having brought the first ACLY inhibitor to the market. Along with the implementation of leading-edge discovery technology and data science approaches, we aim to reveal new therapeutic opportunities and develop next-generation inhibitors optimized to address multiple life-threatening diseases.